Article

Immunopharmacological consequences of immune responses to therapeutic interferon beta

2013-01-01

Abstract excerpt

Protein therapeutics or biologics represent 30 % of current licensed pharmaceutical products. In general, biologics offer superior safety profiles compared to small molecules. However, significant clinical concerns have emerged in terms of development of anti-drug antibodies (ADAs), a phenomenon that is covered under the term, immunogenicity. Anti-drug antibodies can alter pharmacokinetics, reduce efficacy of the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: eaf9c0d3-8a4f-5b25-897a-c959e95f631d
DOI: 10.17638/00015173

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunopharmacological consequences of immune responses to therapeutic interferon betaDOI 10.17638/00015173Read

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.Semantic proximity Read

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-betaSemantic proximity Read

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).Semantic proximity Read

Management of adverse reactions to biologic agents.Semantic proximity Read

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.Semantic proximity Read

In Silico and In Vitro Investigations On Mutated IFNβ-scFv Against Human Collagen Type IISemantic proximity Read

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.Semantic proximity Read

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.Semantic proximity Read

An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta ProductsSemantic proximity Read

A New Venue of TNF TargetingSemantic proximity Read

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.Semantic proximity Read

Interferon-beta changes the expression of IL10, IL23A and FOXP3 on Multiple Sclerosis patients' T cellsSemantic proximity Read